Published in Mult Scler on April 01, 2002
The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60
Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med (2005) 2.30
Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell (2016) 2.24
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord (2011) 1.19
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. Arch Neurol (2008) 1.10
Teriflunomide and its mechanism of action in multiple sclerosis. Drugs (2014) 1.08
The immunosuppressive side of PDT. Photochem Photobiol Sci (2011) 0.86
Effects of prophylactic administration of bacteriophages to immunosuppressed mice infected with Staphylococcus aureus. BMC Microbiol (2009) 0.85
Chemotherapeutics in the treatment of multiple sclerosis. Ther Adv Neurol Disord (2010) 0.85
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. J Neurol (2004) 0.83
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr Neuropharmacol (2011) 0.82
Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis. Neurotherapeutics (2016) 0.81
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up. J Neurol (2005) 0.81
Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol (2006) 0.80
Quercetin mitigates Adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.79
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance. Mult Scler (2011) 0.78
Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin Exp Immunol (2009) 0.77
High-dose chemotherapy and multiple sclerosis. Curr Opin Oncol (2011) 0.75
Structure of the replicative form of bacteriphage phi X174. VI. Studies on alkali-denatured double-stranded phi X DNA. J Mol Biol (1968) 11.10
Structure of the replicative form of bacteriophage phi-X-174. VII. Renaturation of denatured double-stranded phi-X DNA. J Mol Biol (1969) 10.46
Studies on mustard gas (betabeta'-dichlorodiethyl sulphide) and some related compounds: 5. The fate of injected mustard gas (containing radioactive sulphur) in the animal body. Biochem J (1946) 4.41
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology (2004) 2.50
Experimental allergic encephalomyelitis and multiple sclerosis: lesion characterization with magnetization transfer imaging. Radiology (1992) 2.41
A quantitative assay for DNA-DNA hybrids using membrane filters. Biochem Biophys Res Commun (1966) 2.32
Loss of suppressor T cells in active multiple sclerosis. Analysis with monoclonal antibodies. N Engl J Med (1980) 2.21
The mechanism of damage to the bone marrow in systemic poisoning with mustard gas. Biochem J (1947) 2.16
The SGOT/SGPT ratio--an indicator of alcoholic liver disease. Dig Dis Sci (1979) 2.12
Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology (2008) 2.04
Different inherited levels of DNA repair replication in xeroderma pigmentosum cell strains after exposure to ultraviolet irradiation. Mutat Res (1970) 2.03
Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects. J Infect Dis (1993) 1.92
Risk factors for distal symmetric neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care (1994) 1.74
Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins. J Neurochem (1999) 1.73
Adsorption of monovalent and divalent cations by phospholipid membranes. The monomer-dimer problem. Biophys J (1981) 1.55
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A (1987) 1.52
Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris. J Am Acad Dermatol (2000) 1.51
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology (2003) 1.46
Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology (2005) 1.43
Confirmation by magnetic resonance imaging of optic nerve injury after retrobulbar anesthesia. Arch Ophthalmol (1996) 1.41
Multiple sclerosis: the importance of early recognition and treatment. Cleve Clin J Med (2001) 1.40
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene (1989) 1.34
Contractile effects of a calcium ionophore. Nature (1973) 1.31
Formation of complexes between DNA isolated from tobacco crown gall tumours and RNA complementary to Agrobacterium tumefaciens DNA. Biochim Biophys Acta (1967) 1.30
Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res (1990) 1.26
Distal splenorenal shunt vs. portal-systemic shunt: current status of a controlled trial. Hepatology (1981) 1.24
An improved fit to Website osmotic pressure data. Biophys J (1997) 1.20
Limiting dilution analysis of the frequency of antigen-reactive lymphocytes isolated from the central nervous system of Lewis rats with experimental allergic encephalomyelitis. Cell Immunol (1987) 1.20
Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons. J Comp Neurol (1993) 1.20
Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve (2009) 1.19
Left-sided heart failure presenting as hepatitis. Gastroenterology (1978) 1.19
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol (2014) 1.18
The face, beauty, and symmetry: perceiving asymmetry in beautiful faces. Int J Neurosci (2005) 1.17
Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler (2009) 1.15
Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler (2007) 1.14
Interaction of charged lipid vesicles with planar bilayer lipid membranes: detection by antibiotic membrane probes. J Supramol Struct (1976) 1.13
Binding of type 3 reovirus by a domain of the sigma 1 protein important for hemagglutination leads to infection of murine erythroleukemia cells. J Clin Invest (1992) 1.12
Increased target specificity of anti-HER2 genospheres by modification of surface charge and degree of PEGylation. Mol Pharm (2006) 1.11
Evaluation of distal symmetric polyneuropathy: the role of laboratory and genetic testing (an evidence-based review). Muscle Nerve (2009) 1.09
Bilateral orbital varices associated with habitual bending. Arch Ophthalmol (1995) 1.08
Management of multiple sclerosis. N Engl J Med (1997) 1.08
Structure of the replicative form of bacteriophage phi-X-174. Physico-chemical studies. Biochim Biophys Acta (1966) 1.07
Murine macrophages stimulated with central and peripheral nervous system myelin or purified myelin proteins release inflammatory products. Neurosci Lett (2000) 1.06
Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-beta system. Kidney Int (1998) 1.06
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler (2013) 1.05
Microscopic disease in normal-appearing white matter on conventional MR images in patients with multiple sclerosis: assessment with magnetization-transfer measurements. Radiology (1995) 1.05
Distal symmetrical polyneuropathy: definition for clinical research. Muscle Nerve (2005) 1.04
Treatment for sexually abused children and adolescents. Am Psychol (2000) 1.04
Secondary penile malignancies: the spectrum of presentation. J Surg Oncol (1992) 1.03
Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A (1989) 1.03
Identification of the A-band localization domain of myosin binding proteins C and H (MyBP-C, MyBP-H) in skeletal muscle. J Cell Sci (1999) 1.03
Sedimentation-viscosity studies of high molecular weight DNA. J Mol Biol (1965) 1.02
Treatment of chickenpox pneumonia with adenine arabinoside. Lancet (1979) 1.00
Sterically stabilized liposomes: physical and biological properties. J Drug Target (1994) 0.99
Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and nonenhanced T1-weighted images. AJNR Am J Neuroradiol (1995) 0.98
Serum angiotensin-converting enzyme in multiple sclerosis. Arch Neurol (1997) 0.98
Distribution of neu (c-erbB-2) protein in human skin. J Invest Dermatol (1989) 0.96
A randomized blinded trial of combination therapy with cyclophosphamide in patients-with active multiple sclerosis on interferon beta. Mult Scler (2005) 0.94
Evolution of renal function abnormalities in the db/db mouse that parallels the development of human diabetic nephropathy. Exp Nephrol (1996) 0.93
Characterization of multiple sclerosis plaques with T1-weighted MR and quantitative magnetization transfer. AJNR Am J Neuroradiol (1995) 0.92
Glycated albumin stimulation of PKC-beta activity is linked to increased collagen IV in mesangial cells. Am J Physiol (1999) 0.91
Stoichiometric and electrostatic characterization of calcium binding to native and lipid-substituted adenosinetriphosphatase of sarcoplasmic reticulum. Biochim Biophys Acta (1985) 0.90
Tubular alterations produced by osmotic diuresis with mannitol. Ann Intern Med (1965) 0.90
Two functional states of sarcoplasmic reticulum ATPase. Biochemistry (1976) 0.89
Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology (2000) 0.88
Post-traumatic torticollis. Neurology (1989) 0.88
Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology (2012) 0.87
Subarachnoid hemorrhage precipitated by cocaine snorting. Arch Neurol (1984) 0.86
The transcription in vitro of various forms of phiX174 DNA. Biochim Biophys Acta (1969) 0.86
Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. Magn Reson Med (1994) 0.85
Total homocysteine is associated with nephropathy in non-insulin-dependent diabetes mellitus. Metabolism (1999) 0.84
Prevention of decline in renal function in the diabetic db/db mouse. Diabetologia (1996) 0.84
Unexpected bronchospasm during spinal anesthesia. J Clin Anesth (1990) 0.84
Thalamic infarction producing aphasia. Mt Sinai J Med (1980) 0.83
Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler (2009) 0.83
Hexosaminidase A activity and amyotrophic lateral sclerosis. Muscle Nerve (1988) 0.83
Glycated albumin stimulates fibronectin and collagen IV production by glomerular endothelial cells under normoglycemic conditions. Biochem Biophys Res Commun (1997) 0.83
Activated coagulation time method for control of heparin is reliable during cardiopulmonary bypass. Anesthesiology (1984) 0.82
Multiple sclerosis lesions: relationship between MR enhancement pattern and magnetization transfer effect. AJNR Am J Neuroradiol (1996) 0.82
Neurogenic pulmonary edema: a sequella of non-hemorrhagic cerebrovascular accidents. Angiology (1976) 0.81
Isolation and characterization of human gingival microvascular endothelial cells. J Periodontal Res (2008) 0.81
MR proton spectroscopy in multiple sclerosis. AJNR Am J Neuroradiol (1992) 0.81
Blood flow and relative tissue PO2 of brain and muscle: effect of various gas mixtures. Am J Physiol (1976) 0.81
The transcription of bacteriophage phi-X-174 DNA. Biochim Biophys Acta (1970) 0.80
The American Society of Anesthesiologists' Physical Status: category V revisited. J Clin Anesth (2000) 0.80
Plant-determined variation in cardenolide content and thin-layer chromatography profiles of monarch butterflies,Danaus plexippus reared on milkweed plants in California : 3. Asclepias californica. J Chem Ecol (1984) 0.80
Suture loop to aid in ganciclovir implant removal. Arch Ophthalmol (1999) 0.80
Mass-action formulations of monovalent and divalent cation adsorption by phospholipid membranes. Biophys J (1984) 0.80
The calcified intervertebral disc. A non-specific roentgenologic sign. J Med Soc N J (1973) 0.79